(HealthDay)—Vyvgart (efgartigimod), a neonatal Fc receptor blocker (FcRn), was approved to treat generalized myasthenia gravis in adults who test positive for the anti-acetylcholine receptor (AChR) antibody, the U.S. Food ...
Dec 21, 2021
0
6
Argenx, a Belgium pharmaceutical company, recently announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living ...
Jun 18, 2021
0
3
(HealthDay)—In new evidence-based clinical guidelines published in the May 7 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, recommendations are presented for diagnosing, ...
May 19, 2021
0
2
A study of 181 patients at 16 sites across the country who test negative for two antibodies long known to cause muscle-weakening myasthenia gravis, found that about 15% test positive for one of two newly discovered antibodies ...
Aug 19, 2020
0
5
Argenx, a Belgian drug maker, recently announced a successful phase 3 ADAPT trial of its experimental drug, efgartigimod. The company plans to seek U.S. approval of the drug by the end of year as a potential new treatment ...
May 29, 2020
0
12
University of Alberta researchers have identified a unique biological marker that can be used to identify the presence of the rare autoimmune disease myasthenia gravis, predict the course of the disease and identify new, ...
Aug 29, 2019
0
5
Clinicians at the Department of Neurology of MedUni Vienna/Vienna General Hospital identified muscle weakness and severe fatigue in a previously healthy patient, to the extent that he was soon confined to a wheelchair. These ...
May 8, 2019
0
0
Quite literally meaning "grave muscle weakness," myasthenia gravis is a chronic autoimmune disorder that causes serious weakening of skeletal muscles responsible for movements such as ocular motion, eye-opening, swallowing, ...
Nov 30, 2018
0
1
A new Yale-led study helps explain why some myasthenia gravis (MG) patients relapse after initially responding to a drug called rituximab, commonly used to treat the incurable autoimmune disease marked by muscle weakness ...
Sep 8, 2017
0
0
In a global study of myasthenia gravis, an autoimmune disease that causes muscle weakness and fatigue, researchers found that surgical removal of an organ called the thymus reduced patients' weakness, and their need for immunosuppressive ...
Aug 10, 2016
0
42
